S&P 500   4,284.37 (+0.24%)
DOW   33,969.58 (-0.03%)
QQQ   329.18 (+0.21%)
AAPL   174.12 (-0.25%)
MSFT   290.80 (-0.18%)
META   175.08 (+0.13%)
GOOGL   120.38 (+0.69%)
AMZN   141.91 (-0.13%)
TSLA   908.61 (-0.37%)
NVDA   187.12 (+2.06%)
NIO   19.88 (-1.00%)
BABA   90.71 (+1.05%)
AMD   100.48 (+2.25%)
MU   63.06 (+2.34%)
T   18.50 (+0.43%)
CGC   3.72 (-8.37%)
F   16.14 (+0.69%)
GE   79.34 (-0.73%)
DIS   122.67 (-0.11%)
AMC   19.64 (-8.05%)
PYPL   99.99 (+0.57%)
PFE   48.64 (-1.28%)
NFLX   244.77 (+1.50%)
S&P 500   4,284.37 (+0.24%)
DOW   33,969.58 (-0.03%)
QQQ   329.18 (+0.21%)
AAPL   174.12 (-0.25%)
MSFT   290.80 (-0.18%)
META   175.08 (+0.13%)
GOOGL   120.38 (+0.69%)
AMZN   141.91 (-0.13%)
TSLA   908.61 (-0.37%)
NVDA   187.12 (+2.06%)
NIO   19.88 (-1.00%)
BABA   90.71 (+1.05%)
AMD   100.48 (+2.25%)
MU   63.06 (+2.34%)
T   18.50 (+0.43%)
CGC   3.72 (-8.37%)
F   16.14 (+0.69%)
GE   79.34 (-0.73%)
DIS   122.67 (-0.11%)
AMC   19.64 (-8.05%)
PYPL   99.99 (+0.57%)
PFE   48.64 (-1.28%)
NFLX   244.77 (+1.50%)
S&P 500   4,284.37 (+0.24%)
DOW   33,969.58 (-0.03%)
QQQ   329.18 (+0.21%)
AAPL   174.12 (-0.25%)
MSFT   290.80 (-0.18%)
META   175.08 (+0.13%)
GOOGL   120.38 (+0.69%)
AMZN   141.91 (-0.13%)
TSLA   908.61 (-0.37%)
NVDA   187.12 (+2.06%)
NIO   19.88 (-1.00%)
BABA   90.71 (+1.05%)
AMD   100.48 (+2.25%)
MU   63.06 (+2.34%)
T   18.50 (+0.43%)
CGC   3.72 (-8.37%)
F   16.14 (+0.69%)
GE   79.34 (-0.73%)
DIS   122.67 (-0.11%)
AMC   19.64 (-8.05%)
PYPL   99.99 (+0.57%)
PFE   48.64 (-1.28%)
NFLX   244.77 (+1.50%)
S&P 500   4,284.37 (+0.24%)
DOW   33,969.58 (-0.03%)
QQQ   329.18 (+0.21%)
AAPL   174.12 (-0.25%)
MSFT   290.80 (-0.18%)
META   175.08 (+0.13%)
GOOGL   120.38 (+0.69%)
AMZN   141.91 (-0.13%)
TSLA   908.61 (-0.37%)
NVDA   187.12 (+2.06%)
NIO   19.88 (-1.00%)
BABA   90.71 (+1.05%)
AMD   100.48 (+2.25%)
MU   63.06 (+2.34%)
T   18.50 (+0.43%)
CGC   3.72 (-8.37%)
F   16.14 (+0.69%)
GE   79.34 (-0.73%)
DIS   122.67 (-0.11%)
AMC   19.64 (-8.05%)
PYPL   99.99 (+0.57%)
PFE   48.64 (-1.28%)
NFLX   244.77 (+1.50%)
NYSE:BHVN

Biohaven Pharmaceutical - BHVN Stock Forecast, Price & News

$148.07
+0.06 (+0.04%)
(As of 08/18/2022 02:46 PM ET)
Add
Compare
Today's Range
$147.96
$148.10
50-Day Range
$143.71
$148.01
52-Week Range
$79.01
$151.51
Volume
2,849 shs
Average Volume
529,230 shs
Market Capitalization
$10.59 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$157.17

Biohaven Pharmaceutical MarketRank™ Forecast

Analyst Rating
Hold
2.29 Rating Score
Upside/​Downside
6.1% Upside
$157.17 Price Target
Short Interest
Healthy
8.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.20mentions of Biohaven Pharmaceutical in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($11.16) to ($7.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.24 out of 5 stars

Medical Sector

1097th out of 1,119 stocks

Pharmaceutical Preparations Industry

537th out of 549 stocks

BHVN stock logo

About Biohaven Pharmaceutical (NYSE:BHVN) Stock

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Analyst Upgrades and Downgrades

BHVN has been the subject of several analyst reports. HC Wainwright downgraded Biohaven Pharmaceutical from a "buy" rating to a "neutral" rating in a report on Wednesday, May 11th. SVB Leerink downgraded Biohaven Pharmaceutical from an "outperform" rating to a "market perform" rating and set a $150.00 price target for the company. in a report on Wednesday, May 11th. Wedbush downgraded Biohaven Pharmaceutical from an "outperform" rating to a "neutral" rating and set a $148.50 price objective for the company. in a report on Monday, August 8th. Cantor Fitzgerald downgraded Biohaven Pharmaceutical from an "overweight" rating to a "neutral" rating in a report on Wednesday, May 11th. Finally, Piper Sandler dropped their price objective on Biohaven Pharmaceutical from $156.00 to $149.00 and set a "na" rating for the company in a report on Tuesday, May 24th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, Biohaven Pharmaceutical currently has a consensus rating of "Hold" and an average target price of $157.17.

Biohaven Pharmaceutical Stock Performance

Biohaven Pharmaceutical stock remained flat at $148.01 during trading on Wednesday. 219,844 shares of the company were exchanged, compared to its average volume of 1,080,780. The business's 50-day simple moving average is $145.73 and its 200-day simple moving average is $131.52. Biohaven Pharmaceutical has a 12-month low of $79.01 and a 12-month high of $151.51. The company has a market cap of $10.58 billion, a price-to-earnings ratio of -9.99 and a beta of 1.03.

Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BHVN Stock News Headlines

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates BHVN, MANT, SWCH
See More Headlines
Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BHVN Company Calendar

Last Earnings
11/08/2021
Today
8/18/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Previous Symbol
NASDAQ:BHVN
Fax
N/A
Employees
928
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$157.17
High Stock Price Forecast
$177.00
Low Stock Price Forecast
$146.00
Forecasted Upside/Downside
+6.1%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
7 Analysts

Profitability

Net Income
$-846,590,000.00
Net Margins
-108.04%
Pretax Margin
-105.78%

Debt

Sales & Book Value

Annual Sales
$462.51 million
Book Value
($11.27) per share

Miscellaneous

Free Float
62,630,000
Market Cap
$10.59 billion
Optionable
Optionable
Beta
1.03

Key Executives














BHVN Stock - Frequently Asked Questions

Should I buy or sell Biohaven Pharmaceutical stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last twelve months. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BHVN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHVN, but not buy additional shares or sell existing shares.
View BHVN analyst ratings
or view top-rated stocks.

What is Biohaven Pharmaceutical's stock price forecast for 2022?

7 Wall Street research analysts have issued 1 year price targets for Biohaven Pharmaceutical's stock. Their BHVN share price forecasts range from $146.00 to $177.00. On average, they predict the company's share price to reach $157.17 in the next year. This suggests a possible upside of 6.2% from the stock's current price.
View analysts price targets for BHVN
or view top-rated stocks among Wall Street analysts.

How have BHVN shares performed in 2022?

Biohaven Pharmaceutical's stock was trading at $137.81 at the start of the year. Since then, BHVN stock has increased by 7.4% and is now trading at $148.01.
View the best growth stocks for 2022 here
.

When is Biohaven Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our BHVN earnings forecast
.

How were Biohaven Pharmaceutical's earnings last quarter?

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) posted its quarterly earnings results on Monday, November, 8th. The company reported ($2.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.40) by $0.23. The company had revenue of $135.74 million for the quarter, compared to the consensus estimate of $128.40 million. The company's revenue was up 668.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($3.27) EPS.

What other stocks do shareholders of Biohaven Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven Pharmaceutical IPO?

(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

What is Biohaven Pharmaceutical's stock symbol?

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Who are Biohaven Pharmaceutical's major shareholders?

Biohaven Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (2.44%), Pentwater Capital Management LP (2.00%), Soros Fund Management LLC (1.76%), TIG Advisors LLC (1.44%), Allspring Global Investments Holdings LLC (1.29%) and JPMorgan Chase & Co. (1.23%). Insiders that own company stock include Declan Doogan, Elyse Stock, Eric Aguiar, George C Clark, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Robert Berman and William A Jones Jr.
View institutional ownership trends
.

How do I buy shares of Biohaven Pharmaceutical?

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biohaven Pharmaceutical's stock price today?

One share of BHVN stock can currently be purchased for approximately $148.01.

How much money does Biohaven Pharmaceutical make?

Biohaven Pharmaceutical (NYSE:BHVN) has a market capitalization of $10.58 billion and generates $462.51 million in revenue each year. The company earns $-846,590,000.00 in net income (profit) each year or ($14.82) on an earnings per share basis.

How many employees does Biohaven Pharmaceutical have?

The company employs 928 workers across the globe.

How can I contact Biohaven Pharmaceutical?

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The official website for the company is www.biohavenpharma.com. The company can be reached via phone at (203) 404-0410 or via email at jennifer.porcelli@biohavenpharma.com.

This page (NYSE:BHVN) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.